Aa
Aa
A
A
A
Close
Avatar universal

Hep B drug pipepline and dates


Hepatitis B therapy pipeline
Project
Company
Pharmacology
Trial ID
Data due?
Phase II
GS-9620
Gilead Sciences
TLR7 agonist
NCT02166047 & NCT02579382
Imminent & Dec 2016
GS-4774
Gilead Sciences/Globeimmune
Therapeutic vaccine
NCT02174276
Imminent
Myrcludex B
Hepatera
Viral entry inhibitor
NCT02637999
Imminent
REP 2139
Replicor
HBsAg release inhibitor
NCT02726789
Sep 2016
ARC-520
Arrowhead Pharmaceuticals
RNAi therapeutic
NCT02604199 and 4 others
Oct 2016
ARB-1467
Arbutus Biopharma
RNAi therapeutic
NCT02631096
Oct 2016
CMX157
Chimerix/Contravir
NNRTI
NCT02710604
Oct 2016
GC1102
Green Cross (Korea)
Recombinant hep B immunoglobulin
NCT02569372
May 2017
RO6864018
Roche
Not disclosed
NCT02391805
Sep 2017
SB 9200
Spring Bank Pharmaceuticals
RIG-I & NOD2 activator
NCT02751996
Dec 2017
REP 2165
Replicor
HBsAg release inhibitor
NCT02565719
Sep 2018
Phase I
NVR 3-778
Johnson & Johnson
Capsid inhibitor
NCT02401737
Imminent
JNJ-56136379
Johnson & Johnson
Not disclosed
NCT02662712
Nov 2016
IONIS-HBV-LRx
GlaxoSmithKline/Ionis
Hepatitis B antisense
NCT02647281
Nov 2016
HepTcell (FP-02.2)
Altimmune
Therapeutic vaccine
NCT02496897
Feb 2017
RO7020322
Roche
Not disclosed
NCT02604355
Apr 2017
ARC-521
Arrowhead Pharmaceuticals
ccc DNA-targeting RNAi
NCT02797522
Jun 2017
TG1050
Transgene
Therapeutic vaccine
NCT02428400
Mar 2018
INO-1800/RG7944
Inovio Pharmaceuticals
Therapeutic vaccine
NCT02431312
Dec 2018
RG7834
Roche
Not disclosed

(1st pt in Q4 2015)
AIC649
Aicuris
Therapeutic vaccine


EYP001
Enyo Pharma
Farnesoid X receptor agonist


GSK3228836
GlaxoSmithKline/Ionis
Hepatitis B antisense


Source: EvaluatePharma and Clinicaltrials.gov.
9 Responses
Avatar universal
more readable form here :)

http://www.hepb.org/treatment-and-management/drug-watch/
2 Comments
The problem is that copying the link from this site is problematic
This one has the dates!
Avatar universal
http://seekingalpha.com/article/4000028-hepatitis-b-developers-try-repeat-gileads-hep-c-trick
Avatar universal

Hepatitis B therapy pipeline
Project / Company / Pharmacology / Trial ID / Data due?
Phase II
GS-9620 Giled Sciences TLR7 agonist NCT02166047 & NCT02579382 Imminent & Dec 2016
GS-4774 Sciences/Globeimmune Therapeutic vaccine NCT02174276 Imminent
Myrcludex B Viral entry inhibitor NCT02637999 Imminent
REP 2139 Replicor HBsAg release inhibitor
NCT02726789 Sep 2016
ARC-520 Arrowhead Pharmaceuticals RNAi therapeutic NCT02604199 and 4 others Oct 2016
ARB-1467 Arbutus Biopharma RNAi therapeutic NCT02631096 Oct 2016
CMX157 Chimerix/Contravir NNRTI NCT02710604 Oct 2016
GC1102 Green Cross (Korea) Recombinant hep B immunoglobulin NCT02569372 May 2017
RO6864018 Roche Not disclosed NCT02391805 Sep 2017
SB 9200 Spring Bank Pharmaceuticals RIG-I & NOD2 activator NCT02751996 Dec 2017
REP 2165 Replicor HBsAg release inhibitor NCT02565719 Sep 2018
Phase I
NVR 3-778 Johnson & Johnson Capsid inhibitor NCT02401737 Imminent
JNJ-56136379 Johnson & Johnson Not disclosed NCT02662712 Nov 2016
IONIS-HBV-LRx GlaxoSmithKline/Ionis Hepatitis B antisense NCT02647281 Nov 2016
HepTcell (FP-02.2) Altimmune Therapeutic vaccine NCT02496897 Feb 2017 RO7020322 Roche Not disclosed NCT02604355 Apr 2017
ARC-521 Arrowhead Pharmaceuticals ccc DNA-targeting RNAi NCT02797522 Jun 2017
TG1050 Transgene Therapeutic vaccine NCT02428400 Mar 2018
INO-1800/RG7944 Inovio Pharmaceuticals Therapeutic vaccine NCT02431312 Dec 2018
RG7834 Roche Not disclosed – (1st pt in Q4 2015)
AIC649 Aicuris Therapeutic vaccine – –
EYP001 Enyo Pharma Farnesoid X receptor agonist – –
GSK3228836 GlaxoSmithKline/Ionis Hepatitis B antisense – –
Source: EvaluatePharma and Clinicaltrials.gov.
Avatar universal
This is a very comprehensive and timely article about HBV drugs in development. ABX203 was not mentioned, even though one clinical trial is still on-going. Most of the others are well-known to us all - very hard to get excited about.
It would be interesting to know more about the "undisclosed mechanism" of the Johnson& Johnson and Roach's drugs. It is hard to tell whether they do not want to disclose because they are just like the others or represent some new approaches.
1 Comments
Couple months ago they announced that they gave up on ABX203
Avatar universal
I feel the only leading HBV drug on pipeline is ARWR( Arc-520).
1 Comments
Recently, Arrowhead Pharmaceuticals reported that combining ARC-520 and Bristol-Myers Squibb's (NYSE:BMY) Baraclude resulted in up to 5.5 log, or 99.99% reductions in serum HBV DNA. Patients with HBeAg-negative mutation -- a tough-to-treat variation -- achieved reductions that put them below the limit of quantification, too.

Those results boost confidence that ARC-520 combination therapy could provide a functional cure for the 350-million-plus people worldwide who are infected with hepatitis B.
Avatar universal
It is 5.5 log reduction in hbvdna, not HBsAg. Since patients are on Entecavir, these types of reduction in hbvdna are not unusual.
Avatar universal
Press release from Abivax:

* Post-treatment monitoring of patients will be continued as per protocol in order to provide additional insight on clinical trial outcomes and secondary endpoints

* Future development of ABX203 under review, including addition of an adjuvant, new administration schedules and therapeutic combinations

Avatar universal
i feel like some new drug by 2020, lets c.
1 Comments
It is coming before 2020 but for Hbeag -
Avatar universal
not Hbeag-
Have an Answer?

You are reading content posted in the Hepatitis B Community

Didn't find the answer you were looking for?
Ask a question
Popular Resources
For people with Obsessive-Compulsive Disorder (OCD), the COVID-19 pandemic can be particularly challenging.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Here’s how your baby’s growing in your body each week.
These common ADD/ADHD myths could already be hurting your child
This article will tell you more about strength training at home, giving you some options that require little to no equipment.
In You Can Prevent a Stroke, Dr. Joshua Yamamoto and Dr. Kristin Thomas help us understand what we can do to prevent a stroke.